A little overlooked asset of this group may hold the fate of...

A little overlooked asset of this group may hold the fate of many hepatitis suffers in its grasp....

Once accepted by TGA this will add to this groups China play---incidently on of the largest host countries


PHARMASAFE PTY LTD
Pharmasafe Pty Ltd’s (“Pharmasafe”) application for a herbal based product to reduce the effects of hepatitis B was withdrawn last year after the Australian Therapeutic Goods Administration (“TGA”) sought a change to one ingredient. The change required substituting a non-herbal ingredient with a herbal alternative. This has now been undertaken with tests indicating similar results. Accordingly, re-submission to TGA for approval is being prepared with lodgement anticipated before December 2004. An acceptance is expected in the New Year.

Extract from Aust Gov sources

“Public health significance & occurrence
Hepatitis B virus is a major cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma.
An estimated two billion people have been infected with HBV worldwide, 350 million of whom are chronic carriers. Each year an estimated one million people die as a result of HBV infections and over four million new acute clinical cases occur.
In countries with low endemicity (HBsAg prevalence less than 2%) most infections occur in young adults and especially among persons who belong to known high risk groups. Risk of HBV infection increases with:
• unprotected sexual contact
• injecting drug use
• household and sexual contact with known HBV infected persons
• incarceration
• workplace exposure to blood.
In higher endemicity areas (HBsAg prevalence ? 2%) most infections occur as a result of perinatal transmission from HBsAg-positive mothers or early horizontal transmission via close contact in the household family setting.”